A detailed history of Legal & General Group PLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 46,457 shares of CGEM stock, worth $558,413. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,457
Previous 46,457 -0.0%
Holding current value
$558,413
Previous $777,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.03 - $20.86 $35,939 - $46,768
2,242 Added 5.07%
46,457 $777,000
Q2 2024

Aug 14, 2024

BUY
$15.63 - $29.35 $385,342 - $723,594
24,654 Added 126.04%
44,215 $771,000
Q1 2024

May 14, 2024

BUY
$10.17 - $19.02 $56,463 - $105,599
5,552 Added 39.63%
19,561 $333,000
Q3 2023

Nov 14, 2023

SELL
$9.05 - $11.72 $5,086 - $6,586
-562 Reduced 3.86%
14,009 $126,000
Q2 2023

Aug 14, 2023

BUY
$8.8 - $13.4 $69,704 - $106,141
7,921 Added 119.11%
14,571 $156,000
Q1 2023

May 15, 2023

BUY
$10.2 - $11.91 $6,477 - $7,562
635 Added 10.56%
6,650 $68,000
Q3 2022

Nov 14, 2022

BUY
$11.82 - $15.42 $4,385 - $5,720
371 Added 6.57%
6,015 $77,000
Q2 2022

Aug 22, 2022

SELL
$7.31 - $13.55 $6,396 - $11,856
-875 Reduced 13.42%
5,644 $72,000
Q4 2021

Feb 14, 2022

BUY
$15.36 - $25.0 $11,904 - $19,375
775 Added 13.49%
6,519 $101,000
Q3 2021

Nov 15, 2021

BUY
$22.56 - $29.68 $80,065 - $105,334
3,549 Added 161.69%
5,744 $130,000
Q2 2021

Aug 12, 2021

BUY
$24.96 - $41.25 $20,966 - $34,650
840 Added 61.99%
2,195 $56,000
Q1 2021

May 17, 2021

BUY
$28.0 - $53.42 $37,940 - $72,384
1,355 New
1,355 $56,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $548M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.